Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 16, 79-89
- https://doi.org/10.2147/copd.s291030
Abstract
Background: Three 52-week studies in COPD have assessed the efficacy and safety of single-inhaler extrafine formulation triple therapy combining beclomethasone dipropionate (BDP), formoterol fumarate (FF) and glycopyrronium (G) delivered via pressurized metered-dose inhaler (pMDI). BDP/FF/G is now being developed for delivery via multi-dose dry-powder inhaler (DPI; NEXThaler). This study aimed to demonstrate non-inferiority of BDP/FF/G DPI vs pMDI for lung function. Methods: Multicenter, randomized, double-blind, double-dummy, active-controlled, three-way cross-over study in patients with COPD and post-bronchodilator forced expiratory volume in 1 second (FEV1) 30– 80% predicted. Patients received BDP/FF/G 100/6/10μg via DPI and pMDI, and BDP/FF 100/6μg via pMDI, all two inhalations twice daily for four weeks, with treatments separated by two-week washout. The two co-primary objectives were to demonstrate non-inferiority between the two BDP/FF/G formulations for FEV1 area under the curve between 0 and 12 hours post-dose (AUC0-12h) normalized by time and trough FEV1 at 24 hours, both on Day 28. EudraCT 2017– 004405-41. Results: Of 449 patients screened, 366 were randomized, with 342 (93.4%) completing all three treatment periods. The primary objectives were met, with changes from baseline in FEV1 AUC0– 12h and trough FEV1 on Day 28 similar for the two BDP/FF/G formulations, and the confidence intervals for the difference lying entirely within the pre-specified non-inferiority criterion (– 50mL): – 20 (– 35, – 6) mL and 3 (– 15, 20) mL for AUC0– 12h and trough FEV1, respectively. BDP/FF/G pMDI and DPI were statistically superior to BDP/FF for these endpoints (p< 0.001). A similar proportion of patients experienced adverse events with each treatment (15.5%, 18.7% and 15.4% with BDP/FF/G DPI and pMDI, and BDP/FF, respectively); the majority were mild or moderate, with few related to treatment. Conclusion: Extrafine BDP/FF/G DPI and pMDI demonstrated similar efficacy and safety in patients with COPD, supporting the DPI formulation as a valid alternative.Keywords
This publication has 18 references indexed in Scilit:
- Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN)World Allergy Organization Journal, 2016
- Debates in allergy medicine: baked milk and egg ingestion accelerates resolution of milk and egg allergyWorld Allergy Organization Journal, 2016
- Inhaler Devices for Chronic Obstructive Pulmonary Disease: Insights from Patients and Healthcare PractitionersJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2015
- Dry powder inhalers in COPD, lung inflammation and pulmonary infectionsExpert Opinion on Drug Delivery, 2014
- NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthmaExpert Opinion on Drug Delivery, 2014
- Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPDRespiratory Medicine, 2013
- Inhaler Devices for Patients with COPDCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2013
- Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysisRespiratory Research, 2011
- Inhaler mishandling remains common in real life and is associated with reduced disease controlRespiratory Medicine, 2011
- Regional Lung Deposition and Bronchodilator Response as a Function of β2-Agonist Particle SizeAmerican Journal of Respiratory and Critical Care Medicine, 2005